Business
Apollo Medical Holdings, Inc. Reports Second Quarter 2022 Results
Company to Host Conference Call Today at 2 p.m. PT/5 p.m. ET ALHAMBRA, Calif., Aug. 4, 2022 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and
About this update from Astrana Health Inc.
[{"type":"text","content":"Company to Host Conference Call Today at 2 p.m. PT/5 p.m. ET\nALHAMBRA, Calif., Aug. 4, 2022 /PRNewswire/ -- Apollo Medical Holdings, Inc. (\"ApolloMed,\" and together with its subsidiaries and affiliated entities, the \"Company\") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financial results for the second quarter and six months ended June 30, 2022.\n\n \n \n \n \n \n \n\n \nFinancial Highlights for Second Quarter Ended June 30, 2022:\nTotal revenue of $269.7 million, up 54% from $175.6 million for the prior-year quarterNet income attributable to ApolloMed of $11.4 million, compared to $12.7 million for the prior-year quarterEarnings per share - diluted (\"EPS - diluted\") of $0.25, compared to $0.28 per share for the prior-year quarterAdjusted EBITDA of $36.9 million, up 14% from $32.4 million for the prior-year quarterFinancial Highlights for Six Months Ended June 30, 2022:\nTotal revenue of $533.0 million, up 52% from $351.7 million for the prior-year periodNet income attributable to ApolloMed of $25.7 million, compared to $25.8 million for the prior-year periodEPS-diluted of $0.56, compared to $0.58 per share for the prior-year periodAdjusted EBITDA of $75.1 million, up 19% from $63.2 million for the prior-year periodCash and cash equivalents of $234.2 million as of June 30, 2022Guidance:\nApolloMed is reiterating the following guidance for total revenue, net income, EBITDA, and Adjusted EBITDA, based on the Company's existing business, current view of existing market conditions and assumptions for the year ending December 31, 2022.\n($ in millions)\n2022 Guidance Range\nLow\nHigh\nTotal revenue\n$ 1,055.0\n$ 1,085.0\nNet income\n$ 38.0\n$ 57.0\nEBITDA\n$ 81.0\n$ 111.0\nAdjusted EBITDA\n$ 136.0\n$ 166.0\nSee \"Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA\" and \"Use of Non-GAAP Financial Measures\" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See \"Forward-Looking Statements\" below for additional information.\nManagement Commentary:\nBrandon Sim, Co-Chief Executive Officer of ApolloMed, added, \"During the second quarter of 2022, we delivered yet another q...